๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Compound trial record
Trackers Drugs Trial finder
Compound · clinical trials

Sonrotoclax

Also listed in trial records as BGB-11417
Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 15 trials in our China, USA, UK and Ireland registers that name Sonrotoclax as an intervention. Synced 24 Sep 2026
15Trials tracked
8Recruiting now
3Lead sponsors
4Country registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 โ€” Top 14 finalist
Compiled from ClinicalTrials.gov registry records ยท Last verified ยท Editorial standards

Sonrotoclax is named as a drug or biological intervention in 15 clinical trials in our China, USA, UK and Ireland trial registers, 8 of which are recruiting. Lead sponsors include BeOne Medicines (12), Ruijin Hospital (2) and Yi Shuhua (1). Registered phases: Phase 1/2, Phase 3, Phase 2 and Phase 1. Conditions studied include Chronic Lymphocytic Leukemia; Mantle Cell Lymphoma; CLL.

01

Clinical trials of Sonrotoclax

15 trials
NCT IDStudyPhaseStatusLead sponsorRegister
NCT06742996 A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL) (ClinicalTrials.gov ↗)
Mantle Cell Lymphoma, B Cell Lymphoma
Phase 3 Recruiting BeOne Medicines UK, USA, China
NCT06943872 A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL) (ClinicalTrials.gov ↗)
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Phase 3 Recruiting BeOne Medicines Ireland, UK, USA, China
NCT07277231 A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
Phase 3 Recruiting BeOne Medicines UK, USA, China
NCT07548710 Study of SA+X in the Treatment of Newly Diagnosed AML (ClinicalTrials.gov ↗)
Acute Myeloid Leukemia
Phase 2 Recruiting Ruijin Hospital China
NCT04771130 A Study of BGB-11417 in Participants With Myeloid Malignancies
Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm
Phase 1/2 Recruiting BeOne Medicines UK, USA, China
NCT04973605 A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma (ClinicalTrials.gov ↗)
Relapsed/Refractory Multiple Myeloma
Phase 1/2 Recruiting BeOne Medicines UK, USA, China
NCT06634589 A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies (ClinicalTrials.gov ↗)
B-cell Malignancy, Relapsed Cancer, Refractory Cancer
Phase 1/2 Recruiting BeOne Medicines USA, China
NCT06697184 A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers. (ClinicalTrials.gov ↗)
Chronic Lymphocytic Leukemia, CLL, Mantle Cell Lymphoma
Phase 1/2 Recruiting BeOne Medicines UK, USA
NCT07682415 Zanubrutinib Induction Followed by Delayed Fixed-Duration Combination With Sonrotoclax for CLL/SLL๏ผšStop Trial 2.0 (ClinicalTrials.gov ↗)
CLL / SLL
Phase 2 Not yet open Yi Shuhua China
NCT07638787 Pola-R-CHP Plus Sonrotoclax in Untreated BCL2-High/Double-Hit LBCL (ClinicalTrials.gov ↗)
Large B-cell Lymphoma
Phase 1/2 Not yet open Ruijin Hospital China
NCT06073821 Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL) (ClinicalTrials.gov ↗)
CLL
Phase 3 Active, closed BeOne Medicines UK, USA, China
NCT05952037 A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenstrรถm Macroglobulinemia (ClinicalTrials.gov ↗)
Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinemia Refractory
Phase 2 Active, closed BeOne Medicines UK, USA, China
NCT06637501 A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
Phase 2 Active, closed BeOne Medicines USA, China
NCT05471843 Study of Sonrotoclax (BGB-11417) Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma (ClinicalTrials.gov ↗)
Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma (MCL), Relapsed Mantle Cell Lymphoma
Phase 1/2 Active, closed BeOne Medicines UK, USA, China
NCT04277637 Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies (ClinicalTrials.gov ↗)
Mature B-Cell Malignancies
Phase 1 Active, closed BeOne Medicines UK, USA

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

02

Conditions studied

22 conditions
Condition (as registered)Trials
Chronic Lymphocytic Leukemia4
Mantle Cell Lymphoma3
CLL2
Acute Myeloid Leukemia2
Small Lymphocytic Lymphoma1
B Cell Lymphoma1
MCL1
Relapsed/Refractory Multiple Myeloma1
Mature B-Cell Malignancies1
Waldenstrom Macroglobulinemia1
Waldenstrom's Macroglobulinemia Recurrent1
Waldenstrom's Macroglobulinemia Refractory1
B-cell Malignancy1
Relapsed Cancer1
Refractory Cancer1
B-cell Lymphoma1
Large B-cell Lymphoma1
CLL / SLL1
Myelodysplastic Syndromes1
Myelodysplastic/Myeloproliferative Neoplasm1
Refractory Mantle Cell Lymphoma (MCL)1
Relapsed Mantle Cell Lymphoma1
03

Sponsors

lead sponsor per trial
Lead sponsorTrials
BeOne Medicines12
Ruijin Hospital2
Yi Shuhua1
04

Trials by country register

A trial with sites in more than one country appears in each of those registers.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records โ€” it is not written from memory, and nothing here describes how Sonrotoclax works or whether it is effective. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Sonrotoclax (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician โ€” our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us โ€” we correct promptly and log it.